Maplight Therapeutics (NASDAQ:MPLT) Insider Sells $93,025.04 in Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) insider James Lillie sold 11,513 shares of Maplight Therapeutics stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $8.08, for a total value of $93,025.04. Following the sale, the insider owned 198,597 shares of the company’s stock, valued at approximately $1,604,663.76. This trade represents a 5.48% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

James Woodruff Lillie also recently made the following trade(s):

• On Monday, August 3rd, James Lillie sold 22,082 shares of Maplight Therapeutics stock. The stock was sold at an average price of $12.54, for a total value of $276,908.28.

Maplight Therapeutics Stock Performance

MPLT traded down $0.32 on Friday, reaching $7.70. The company had a trading volume of 359,069 shares, compared to its average volume of 472,697. The business has a 50 day simple moving average of $11.33 and a 200 day simple moving average of $22.47. The company has a market cap of $427.94 million and a price-to-earnings ratio of -0.18. Maplight Therapeutics, Inc. has a 52-week low of $7.46 and a 52-week high of $40.43.

Maplight Therapeutics (NASDAQ:MPLT) last announced its earnings results on Thursday, August 13th. The company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.40) by $0.08. As a group, equities research analysts predict that Maplight Therapeutics, Inc. will post -5.01 EPS for the current fiscal year.

Institutional Investors Weigh In On Maplight Therapeutics

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. bought a new position in shares of Maplight Therapeutics during the 2nd quarter valued at $36,741,000. Nan Fung Group Holdings Ltd purchased a new position in Maplight Therapeutics in the 2nd quarter worth $34,809,708. 5AM Venture Management LLC bought a new stake in Maplight Therapeutics in the fourth quarter worth $16,687,000. Blue Owl Capital Holdings LP bought a new stake in Maplight Therapeutics in the second quarter worth $26,161,000. Finally, ADAR1 Capital Management LLC purchased a new stake in Maplight Therapeutics during the first quarter valued at about $7,622,000.

Analysts Set New Price Targets

MPLT has been the subject of a number of research analyst reports. BMO Capital Markets began coverage on shares of Maplight Therapeutics in a report on Monday, July 20th. They set an “outperform” rating and a $46.00 price objective for the company. Canaccord Genuity Group set a $21.00 target price on Maplight Therapeutics in a research note on Friday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maplight Therapeutics in a research note on Friday, October 9th. Needham & Company LLC lowered their price target on Maplight Therapeutics from $45.00 to $43.00 and set a “buy” rating on the stock in a research report on Monday, August 31st. Finally, Wall Street Zen lowered Maplight Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 3rd. Four equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.50.

About Maplight Therapeutics

MapLight Therapeutics is a clinical-stage biopharmaceutical company developing medicines for neuropsychiatric and neurological disorders. The company focuses on conditions for which existing treatments may provide limited benefits or cause significant side effects.

MapLight uses a neuroscience-focused drug discovery and development approach to identify therapies intended to address the underlying biology of central nervous system disorders. Its pipeline includes investigational small-molecule treatments being studied for conditions such as schizophrenia and other serious mental health disorders.

The company conducts research and clinical development in the United States.